

Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes

Charnita M. Zeigler-Johnson, PhD,¹ Elaine Spangler, MD,¹ Mohamed Jalloh, MD,² Serigne M. Gueye, MD,² Hanna Rennert, MD,³ Timothy R. Rebbeck, PhD^{1,4}

¹Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA

²Hôpital Général de Grand Yoff, Dakar, Sénégal

³Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA

⁴Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA

ZEIGLER-JOHNSON CM, SPANGLER E, JALLOH M, GUEYE SM, RENNERT H, REBBECK TR. Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. *The Canadian Journal of Urology*. 2008;15(1):3872-3882.

Introduction: Disparities in prostate cancer incidence and outcomes are a hallmark of the global pattern of prostate cancer, with men of African descent suffering disproportionately from this disease. The causes of these disparities are poorly understood.

Methods: A review of the literature was undertaken to evaluate the role that genetic susceptibility may play in prostate cancer etiology and outcomes, with a particular emphasis on disparities.

Results: The genetic contribution to prostate cancer is well established, and a number of candidate prostate cancer genes have been identified. Significant differences

in the frequency of risk alleles in these genes have been identified across the major races. These allele frequency differences may in part explain an increased susceptibility to prostate cancer in some populations. In addition, non-genetic factors contribute significantly to prostate cancer disparities, and the cumulative contribution of both genetic and non-genetic factors to poor-prognosis prostate cancer may explain the poorer outcomes experienced by men of African descent.

Conclusions: Prostate cancer disparities are a function of genetic susceptibility as well as environment, behavior, and health care factors acting in the context of this genetic susceptibility. Elimination of global prostate cancer disparities requires a full understanding of the effects of all of these factors on prostate cancer etiology and outcomes.

Key Words: prostate cancer, African descent, genetics, disparities

Accepted for publication December 2007

Acknowledgements

This project was supported by grants to Dr. Timothy R. Rebbeck (RO1-CA85074, P50-CA105641), Dr. Charnita M. Zeigler-Johnson (K07-CA106730), and Dr. Hanna Rennert (Department of Defense W81XWH-05-1-0198).

Address correspondence to Dr. Timothy Rebbeck, Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 904 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021 USA

Introduction

Prostate cancer disproportionately affects men of African descent in terms of incidence, morbidity, and mortality. There are significant gaps in our knowledge about the factors that predict disparities in prostate cancer incidence and outcomes between men of African and European descent. This is true both in the United States as well as other geographic locations, including Africa and the Caribbean. In order to fully understand the source and solution to these disparities, it is imperative to integrate diverse scientific

disciplines, methods, and analytic approaches to understand the multiple contributions to disparities in prostate cancer, including factors associated with the social environment (e.g., economic status, access to health care, social isolation), the physical environment (e.g., location or type of residence or medical care setting), behavior (e.g., attitudes, beliefs, and practices associated with prostate cancer screening), and biology (e.g., inherited genotypes that may affect the development of prostate cancer or predict the aggressiveness of a prostate tumor).

Evidence of global prostate cancer disparities

Prostate cancer has one of the highest incidences and prevalences of any cancer in the world, accounting for 6.9% of all cancers diagnosed. Prostate cancer accounts for 9.7% of all cancers in men, including 15% of cancers in developed countries and 4% of cancers in less developed areas of the world. It is also responsible for almost 6% of cancer deaths in men worldwide. About 600000 new cases of prostate

cancer are diagnosed each year, and approximately 200000 deaths are attributed to prostate cancer. Three-fourths of prostate cancer cases occur in men over the age of 64 years.¹

Prostate cancer rates vary significantly by geographical region, Table 1. The incidence of prostate cancer is highest in countries where prostate-specific antigen (PSA) screening for prostate cancer is common.¹ These rates are influenced greatly by the detection of latent or asymptomatic prostate cancers through the use of screening modalities. Screening with PSA has not been applied in all regions, including Africa, to the same degree as in the United States.

While rates of prostate cancer are high in Europe and North America, the incidence of prostate cancer is highest among men of African descent in North America and the Caribbean. African American men are at particularly high risk for prostate cancer. Recent SEER data (2006) indicate that the incidence of prostate cancer in African American men is higher than in any other group, with an age-adjusted incidence of 255.5 per 100000 versus 161.4 per 100000 in European

TABLE 1. Sample prostate cancer incidence and mortality rates (per 100000)

Region	Subgrouping	Age-specific incidence	Age-specific mortality	Source
World		25.3	8.2	
Developed countries		56.2	13.5	IARC ¹⁰⁵
Developing countries		9.4	5.2	
Africa	Eastern Africa	13.8	11.8	
	Middle Africa	24.5	21.1	
	Northern Africa	5.8	4.9	IARC ¹⁰⁵
	Southern Africa	40.5	22.4	
	Western Africa	19.3	16.0	
Americas	The Caribbean	52.4	28.0	IARC ¹⁰⁵
	Brazil	53.2	15.8	
	United States: all races	168.0	27.9	
	African American	255.5	62.3	
	European American	161.4	25.6	SEER, 2004
	American Indian/ Alaskan Native	68.2	21.5	
	Asian or Pacific Islander	96.5	11.3	
	Hispanic	140.8	21.2	
Asia	Eastern Asia	3.8	1.9	
Europe	Northern Europe	57.5	19.7	IARC ¹⁰⁵
	Western Europe	61.6	17.5	
Oceania	New Zealand	79.9	18.1	

Americans. African American men also present with more advanced disease at initial diagnosis,² and have a worse prognosis than white men.³ However, the reason for these differences is not completely understood. It has been hypothesized that genetics and environmental exposures may play a role in determining these high rates.^{4,5}

Like incidence, prostate cancer mortality rates are highest in populations of African descent. A study by Thompson et al⁶ found that after controlling for prognostic variables, African American men were more likely than European American men to have inferior outcomes after receiving hormonal therapy for prostate cancer. This ethnic disparity suggests that there may be a biological difference in prostate cancer as it manifests in African Americans versus European Americans.

Reported prostate cancer rates are low in native Africans, perhaps due to underreporting of the disease. Although not reflected in many international reports, prostate cancer appears to be one of the most prevalent urological malignancies in native Africans.⁷ Rates in East and West African populations have been reported to be higher than those in North Africa and other developing countries. However, the validity of these rates in West African populations is not known, and it is possible that rates are substantially higher than those reported in the existing registries.⁸

Prostate cancer may pose a significant public health burden in some African countries, as the majority of newly diagnosed cases present with advanced disease, including poor differentiation of the tumor, metastasis, and neurological symptoms.⁹⁻¹² Diagnosis at this later stage of disease often is associated with poor prognosis, which has devastating effects in countries with limited medical resources.^{9,12} Because of differences in screening practices which increase the number of low grade or asymptomatic cancers detected, prostate cancer survival is estimated at 80% in the United States compared to 40% in developing nations.¹ A combination of low socioeconomic status, late disease presentation, and limited health care access for prostate cancer treatment in many African countries may contribute to the poor prognosis that African men face after being diagnosed with prostate cancer.¹³

Because African and African American men have common ancestry, knowledge of prostate cancer in African men, and comparisons of prostate cancer in African American men and men of the African Diaspora may provide valuable clues about the causes, prevention and treatment of prostate cancer. International comparisons of prostate cancer rates are complicated by differences in prostate cancer screening, diagnosis and reporting systems.^{11,14}

Research on prostate cancer disparities by ethnicity has revealed that there are ethnic differences across populations in terms of diagnostic characteristics and prognostic characteristics, with African Americans having an earlier age at diagnosis and higher PSA levels compared with European Americans.^{10,15,16} However, these ethnic disparities are not explained entirely by inequities in socioeconomic status or access to and use of health care.¹⁷

Despite this evidence, the reasons for disparity in prostate cancer etiology and outcomes in men of African descent are not well understood. Previous research has largely identified individual factors that may be associated with prostate cancer risk or disparities, including family history, age, race, and possibly exposures. However, this research has not generally considered the interaction of multiple factors and the neighborhood context in which they act in determining the causes of disparities. A transdisciplinary approach that considers multiple causative agents may be required to fully understand disparities in prostate cancer and the translation of this information into meaningful disparities reduction approaches. Here, we focus on the possible role of genetic susceptibility in affecting prostate cancer disparities.

Genetic susceptibility

Genetic contribution to prostate cancer risk is well established. Men with one, two or three first-degree affected relatives have a 2-, 5- and 11-fold increased risk of developing prostate cancer, respectively.¹⁸ In a study of the risk of prostate cancer among 44788 pairs of twins in the Scandinavian countries, 42% of cases were attributed to inheritance, with the remainder considered to be most likely due to environmental factors.¹⁹ These findings have been confirmed by other studies as well.^{20,21} Epidemiological studies also suggested that about 9% of familial prostate cancer cases diagnosed by age 85 are caused by transmission of a rare high risk allele, and that this allele accounts for approximately half of the prostate cancer cases diagnosed before age 55.¹⁸ Examples of the genes that may explain these effects are provided below.

Candidate androgen metabolism genes

Of the potential candidate gene pathways, a substantial amount of work has been focused on androgen metabolism genetics. Testosterone is a major determinant of prostate growth and differentiation. There are numerous lines of evidence that support the role of androgen metabolism in prostate cancer etiology. Circulating levels of

androgens have been reported to be higher in populations at increased prostate cancer risk, including African American men,²² and lower in populations at decreased prostate cancer risk, such as Chinese men.²³ Although serum levels of testosterone do not correlate well with prostate cancer risk,²⁴ serum levels of dihydrotestosterone (DHT) and other testosterone metabolites do correlate with prostate cancer risk.^{22,24} Second, there is abundant clinical evidence that androgens are related to the growth and development of prostate cancers. Androgen ablation in men with hormone-sensitive prostate cancer reduces tumor size, and decreases the associated disease burden.²⁵ This evidence suggests that the disposition of testosterone may be important in determining prostate cancer risk.

There are several enzymes that determine the activation or inactivation of testosterone, which subsequently influences the signaling capability of testosterone metabolites in androgen-sensitive cells. These genes include the 5 alpha-reductase type II (SRD5A2) and the cytochromes p450 CYP3A4, CYP3A5 and CYP3A43. In addition, the androgen receptor (AR) gene encodes a ligand-activated receptor that mediates androgen signaling response.

The SRD5A2 gene encodes the steroid 5 α -reductase type II, which converts testosterone to DHT. The valine to leucine missense variant at codon 89 (V89L) and the alanine to threonine missense variant at codon 49 (A49T) are common SRD5A2 variants that have been associated with prostate cancer etiology or severity.²⁶⁻³¹ The V89L polymorphism on the SRD5A2 is believed to decrease the conversion of testosterone to DHT³² while A49T is believed to increase the conversion of testosterone to DHT.³⁰ However, associations of prostate cancer risk involving these variants have not been consistent in all studies.^{29,33-40}

The CYP3A multigene family lies in a region of chromosome 7q21-q22, which includes CYP3A4, CYP3A5, CYP3A7 and CYP3A43 in addition to pseudogenes. Only CYP3A4, CYP3A5, CYP3A7, and CYP3A43 are expressed in adults. Previous reports suggested that linkage disequilibrium exists at the CYP3A locus.⁴¹⁻⁴³ Linkage disequilibrium between CYP3A4 and CYP3A5 in particular, suggests that associations at one locus could be the result of causative effects at the other locus.⁴²

The CYP3A genes are involved in the metabolic deactivation (hydroxylation) of testosterone.^{44,45} These genes convert testosterone to 2 β -, 6 β -, or 15 β -hydroxytestosterone, and therefore shunt testosterone away from the more biologically active DHT. However, the function of CYP3A4*1B has been

controversial. In addition to epidemiological evidence that CYP3A4*1B is associated with prostate cancer, the basic science literature has not consistently supported a functionally significant effect. A number of authors have studied the relationship of CYP3A4 expression or function of CYP3A4*1B.⁴⁶⁻⁵² Most of these authors concluded that no biologically meaningful effects existed given the small magnitude of effects that were observed. However, almost all studies have reported consistent elevations in expression associated with CYP3A4*1B in the range of 20%-200% increase over the consensus CYP3A4*1A.

CYP3A5*1 is the only CYP3A5 allele to date that produces high levels of full length CYP3A5 mRNA and expresses CYP3A5.⁴¹ The more common CYP3A5 polymorphism in European Americans, CYP3A5*3, produces an aberrantly spliced mRNA with a premature stop codon. Therefore, there is ample reason to believe that the CYP3A5 alleles studied here could have a functionally meaningful effect on disease etiology. CYP3A5*1 has been inversely associated with prostate cancer.⁴³

In addition, reports have shown a significant association of CYP3A4 and CYP3A43 with occurrence of prostate cancer.⁴² While CYP3A5*1 had no effect on disease occurrence alone in that study, CYP3A43 increased risk of disease in men with a family history of disease, while CYP3A4*1B had an overall protective effect. It is unclear why CYP3A43 is associated with prostate cancer when examined alone. CYP3A43 is preferentially expressed in the prostate,⁵³ but it has rarely been studied. As a result, there is not enough basic science about these genes that can explain the associations with family history-positive prostate cancer. However, one might speculate that this variant is more commonly inherited in men who have a family history of prostate cancer and may be a candidate hereditary gene for prostate cancer.

When CYP3A4 and CYP3A43 were considered in pairwise interactions in our earlier study to determine the effect of having genotypes with at least one CYP3A4*1B and at least one CYP3A43*3 allele, there were highly significant protective effects for early onset prostate cancer.⁴² This is an interesting finding, as it suggests an association that may have its greatest impact in African Americans. While only 4% of European Americans carry this allelic combination, it was a more common haplotype observed in our African American sample (35%). Therefore, a subset of men who carry the CYP3A4*1B and CYP3A43*3 combination and are likely African American are significantly less likely to have been diagnosed with prostate cancer before age 60. The reasons for this

association are not understood, as African Americans, in general, are at high risk to be diagnosed with prostate cancer prior to the age of 60 years.

The androgen receptor (AR), located on the X chromosome, plays a major role in the development and functioning of the prostate gland. AR is expressed in all histologic types and stages of prostate cancer and its transactivation domain is highly polymorphic.⁵⁴ Several regions of repetitive polymorphic DNA sequences exist in AR, including CAG trinucleotide repeats encoding polyglutamine residues and GGN repeats encoding polyglycine residues. Several studies have demonstrated an inverse association between the number of CAG and GGN repeats and risk of prostate cancer, advanced cancer, and risk of associated mortality.⁵⁵⁻⁶² Still, some studies suggest that a positive association exists between prostate cancer and long GGN repeats in combination with short CAG repeats⁶² Vijayalakshmi.⁶³ The combination of GGN/CAG repeats may be the key to understanding how the AR is functioning to promote or inhibit prostate cancer development and progression.⁶²⁻⁶⁴

Race-specific effects

Genotypes involved in prostate cancer etiology differ significantly across ethnicities. For example, the allele frequencies in candidate prostate cancer susceptibility genes such as CYP3A4 and SRD5A2 differ substantially by ethnicity. We have reported a 4-5-fold higher rate of this CYP3A4 variant in African Americans relative to European Americans.⁶⁵ Similarly, Ross et al⁶⁶ and Jaffe et al²⁹ have reported significant ethnic variation in SRD5A2 genotype frequencies that track with race-specific differences in prostate cancer risk. More recently, Zeigler-Johnson et al⁶⁷ reported significant differences in the frequency of V89L variant in the SRD5A2 gene by ethnicity, with an L allele frequency of 30% in European Americans, 27% in African Americans, 19% in Ghanaians, and 18% in Senegalese ($p = 0.002$). Differences were also observed for CYP3A4*1B, with *1B frequencies of 8% in European Americans, 59% in African Americans, 81% in Ghanaians, and 78% in Senegalese ($p = 0.0001$). When these data were pooled with data from previous studies, significant ethnic differences were observed for each of the polymorphisms. Overall, Asians were least likely to have SRD5A2-V89L and CYP3A4*1B while Africans, followed by African Americans, were most likely to have those alleles. These results suggest that ethnicity-specific differences in allele and genotype frequencies exist for candidate prostate cancer genes. They further suggest that prostate cancer risk across ethnicity (lowest in Asians and highest in

African Americans) may be correlated with allele frequencies at candidate prostate cancer susceptibility genes. It remains unknown whether or how these inherited genotypes may explain prostate cancer risk and variability in that risk across racial or ethnic groups. However, these findings suggest that African populations may be at genotypically increased prostate cancer risk, even though the actual magnitude of risk is not well characterized. Because so little is known about the genetics of prostate cancer in Africa, research in this area will provide insight into disease etiology and ethnic disparities worldwide that are associated with prostate cancer incidence and mortality.

Non-candidate susceptibility genes identified by other methods

Family-based studies have yielded numerous prostate cancer susceptibility genes, including ELAC2/HPC2 at 17p (MIM 605367),⁶⁸ 2'-5'-oligoadenylate-dependent RNase L (RNASEL/HPC1) (MIM 180435)⁶⁹ and macrophage scavenger receptor 1 (MSR1) (MIM 153622).⁷⁰ Two of these genes, RNASEL and MSR1 have been shown to play a major role in inflammation and innate immunity.

2'-5'-oligoadenylate-dependent RNase L (RNASEL) is a constitutively expressed latent endonuclease that mediates the antiviral and proapoptotic activities of the interferon-inducible 2-5A system.^{71,72} Initial linkage analysis studies revealed the presence of two deleterious mutations, Met1Ile and Glu265X in African American and European American families, respectively, that segregated with the disease.⁶⁹ Glu265X was also associated with hereditary prostate cancer in other patients from European origin,⁷³ while Met1Ile was not found in other studies. Two additional deleterious frameshift mutations, 471delAAAG and 147dupCAAT, in this gene was detected in Ashkenazi Jewish and Asian Indian men, respectively.⁷⁴ Several missense variants in RNASEL have also been detected.^{73,75} One of these variants, Arg462Gln, was implicated in up to 13% of prostate cancer cases using a family-based case-control study.⁷⁶ Although there is a low frequency of deleterious mutations in RNASEL, functional studies strongly implicate this gene in the disease. Prostate cancer patients carrying the Glu265X or the 471delAAAG mutation showed loss of heterozygosity of the wild type allele in microdissected tumor DNA,^{69,74} while the Arg462Gln had a significantly lower RNASEL enzymatic activity compared to the normal protein.⁷⁶

Macrophage scavenger receptor 1 (MSR1; Chromosome 8p22) is a member of an expanded family of membrane receptors collectively termed scavenger receptors. MSR1 can bind many chemically

modified molecules ranging from bacteria to modified lipoproteins. Correspondingly, MSR1 has been associated with a wide variety of normal and pathological processes, including inflammation, innate and adaptive immunity, oxidative stress and apoptosis.⁷⁷ MSR1 maps to the 8p22 chromosome region, which is commonly deleted in prostate cancer.⁷⁸ Six rare missense variants and one nonsense mutation within MSR1 were observed to co-segregate with the disease in hereditary prostate cancer families.⁷⁰ Furthermore, the prevalence of MSR1 mutations in prostate cancer cases of European and African American descent was substantially higher compared to unaffected men.⁷⁰ Arg293X and Ser41Tyr were the most common mutations detected among prostate cancer patients of European and African American descent, respectively.⁷⁹

ELAC2/HPC2 was predicted to encode an evolutionarily conserved, metal-dependent hydrolase, which could partially explain environmental effects on human prostate epithelial cells by postulating differential interactions with environmental exposures.⁶⁸ ELAC2 was also shown to encode a 3' processing endoribonuclease, an enzyme responsible for the removal of a 3' trailer from precursor RNA⁸⁰ and to interact with γ -tubulin, a component of the mitotic apparatus,⁸¹ suggesting a possible role for ELAC2 in cell cycle control. Initial sequence analyses of the ELAC2 gene identified rare mutations and two common missense changes, Ser217Leu and Ala541Thr that were reported to be associated with prostate

cancer risk.^{68,82,83} However, confirmation of these results has been difficult with only weak consensus among studies.⁸⁴⁻⁸⁵

Race-specific effects

Rennert et al⁸⁶ observed significant differences in ELAC2, RNASEL and MSR1 allele frequencies by race. Although no significant association has been found with prostate cancer risk overall, certain effects for MSR1 IVS7delinsTTA and RNASEL Arg462Gln were observed when stratified by race, family history or disease severity in both African American and European American men. No association between the common ELAC2 Ser217Leu and Ala541Thr sequence variants and prostate cancer risk was found. Moreover, Ala541Thr was very rare among African Americans compared to European Americans, and therefore was unlikely to explain the higher rate of prostate cancer in the African American racial group. RNASEL Arg462Gln gene variation is of particular interest since it was clearly associated with reduced functional activity, and although not statistically significant, it was more common among African American cases compared to controls (0.12 versus 0.16), Table 2. When stratified by prostate tumor characteristics, Arg462Gln was associated with low-grade (OR = 1.5, 95% CI 1.04-2.2) and early-stage (OR = 1.5, 95% CI 1.02-2.1) disease in family history negative European Americans, while in family history positive individuals, Arg462Gln was inversely associated with low grade (OR = 0.43 95% CI 0.21-

TABLE 2. Allele frequencies and SIFT analysis of missense polymorphisms in ELAC2, MSR1 and RNASEL genes

Gene	Nucleotide sequence variant	Amino acid change	Substitution probability (Pi)	Allele frequency (total no. of alleles in sample)			
				African American		European American	
				Controls	Cases	Controls	Cases
ELAC2/	650C > T	Ser217Leu	0.15	0.228 (254) ^a	0.211 (180)	0.296 (656)	0.301 (1020)
HPC2	1621G > A	Ala541Thr	0.26	0.004 (268) ^a	0 (190)	0.027 (698)	0.033 (1072)
MSR1	520G > T	Asp174Tyr	0.13	0.015 (266) ^a	0.022 (186)	0 (696)	0 (1064)
	876C > T	Arg293X	0	0 (262)	0 (166)	0.012 (694) ^b	0.007 (994)
	-14,742A > G	None	N/A	0.269 (260) ^{a,b}	0.253 (186) ^b	0.105 (686)	0.105 (1060)
	IVS5-59C > A	None	N/A	0.012 (246) ^a	0.006 (170)	0.059 (628)	0.050 (968)
	IVS7delTTA	None	N/A	0.264 (220) ^{a,b}	0.218 (156)	0.057 (562)	0.045 (894)
RNASEL/	793G > T	Glu265X	0	0 (268)	0 (188)	0.001 (714)	0.003 (1080)
HPC1	354C > T	None	N/A	0.004 (266)	0 (182)	0.003 (682)	0.002 (1002)
	1385G > A	Arg462Gln	0.02	0.119 (252) ^a	0.159 (176)	0.361 (642)	0.370 (1010)

^aFrequency in control groups differs by race (two-sided Fisher's exact tests: $p < 0.05$).

^bDeviations from Hardy-Weinberg proportions based on χ^2 . Test at $p < 0.05$.

0.88) and low stage (OR = 0.46 95% CI 0.22-0.95) disease. In African Americans however, Arg462Gln was associated with positive family history high stage disease (OR = 14.8 95% CI 1.6-135.7).⁸⁶

These conflicting associations among the different studies may be explained by clinical and genetic heterogeneity of prostate cancer, heterogeneity of study populations, incomplete penetrance, or non-genetic etiologies (e.g., environmental factors). Screening practices for prostate cancer and the inclusion of patients with clinically insignificant disease probably play a role as well. Follow-up meta-analysis studies on the association of prostate cancer with ELAC2, RNASEL, or MSR1 variants found no association or very weak effects of gene variations in these genes with prostate cancer risk overall in either European Americans or African Americans.^{84,85,87-90} However due to power constraints, these studies did not evaluate gene variation effects by disease or prostate tumor characteristics. Taken together, these results suggest that although MSR1 and RNASEL do not seem to be associated with disease risk overall, they may still influence disease severity and that this effect possibly varies by family history of cancer and by racial background.

8q24 locus

Recently, a genome-wide linkage study in Iceland⁹¹ and an admixture study among African Americans⁹² independently detected markers associated with prostate cancer risk on chromosome 8q24. Of these, a single nucleotide, rs1447295, at 8q24.21 (denoted region 1) was most strongly associated with prostate cancer risk in pooled case-control studies of Caucasians from several countries.^{91,93-95} Weaker effects, however, were noted for this SNP among African American men.⁹³ SNP marker rs1447295 was also reported to be associated with prostate cancer aggressiveness, but this effect varied widely by population and study group.^{96,97} Moreover, a second region approximately 350 kb upstream to the previously reported rs1447295, denoted region 2, also demonstrated strong association with prostate cancer^{93,94} in both Caucasians and African Americans. These effects were independent of those detected for region 1. Finally, a third region located between regions 1 and region 2 approximately 70 kb centromeric to rs1447295 was also found to be strongly associated with prostate risk in a large nested case-control study of Caucasians, suggesting the presence of at least two independent loci within 8q24 that may contribute to prostate cancer risk in this population.⁹⁵

Relationship of genotypic susceptibility and other factors

Genetic susceptibility represents only one piece of the very complex nature of prostate cancer etiology. Underlying differences in susceptibility to develop prostate cancer is manifest through exposure to environmental agents, social environmental and neighborhood context, behavior, access to quality health care, and other factors. To fully understand the causes of prostate cancer disparities across groups, a comprehensive approach to the study of many factors involved in prostate cancer causation is required.

Environmental exposure

Relatively few exposures have been consistently associated with prostate cancer risk, and very little information about the role of exposures in establishing prostate cancer disparities is available. Thus, expanded definitions of "the environment" could be developed to include social environment (e.g., socioeconomic status, access to health care, social isolation, cultural beliefs and values); physical environment (e.g., location or type of residence, access to computer and internet resources, or medical care); and behavioral factors (e.g., attitudes, beliefs and practices associated with cancer screening). Thus "environment" could include both individual-level factors as well as neighborhood- or community-level factors using a multilevel approach. For example, neighborhood-level factors could include housing density, measures of social capital such as cultural/civic participation or neighborhood cohesiveness, neighborhood stability such as the percent of rental housing, measures of deprivation such as violent crime rate, and social conditions such as percent of individuals in the neighborhood who live below the poverty level or average educational attainment. Similarly, institutional factors such as health care patterns, access to care, insurance, and type and quality of health care that has been accessed could also be considered. In general, research has focused on individual-level variables, and therefore has not been able to address the larger context in which genes, biological factors, or individual environmental exposures are acting.

Health care

Access to and choice of prostate cancer treatment may have a profound effect on disparities in outcome.⁹⁸ African American men are more likely than European American men to undergo watchful waiting instead of

aggressive therapy for localized prostate cancer⁹⁹⁻¹⁰¹ and differences in treatment and mortality persist after adjusting for individual factors such as stage, grade, and socioeconomic status.⁹⁹ This remains true despite the observation that mortality differences can be explained by lower rates of aggressive treatment in African American men.^{102,103} A strong relationship exists between cancer outcomes and hospital and provider characteristics, prevalent distrust of research/teaching hospitals among African Americans, and links between residential segregation and racial alienation.⁹⁸ However, there remain little data about the role of social environment, including factors that affect access to care, contributes to racial disparities in access to quality prostate cancer treatment.

Social environment and behavior

Social environment, including culture, is increasingly recognized as having an important impact on cancer outcomes in ethnically diverse populations.⁹⁸ Environmental stressors such as life stress, racism, and discrimination may have a deleterious impact on physiological (i.e., immune functioning, cardiovascular reactivity) and behavioral (i.e., coping efforts, dietary behaviors, smoking) responses to prostate cancer.¹⁰⁴ While African ancestry is a marker for other factors that might better explain quality of life, ethnicity alone does not provide information on the causes of these disparities. Incorporating biological and other factors into the application of assessment of risk and outcomes could improve interventions that could be addressed through psycho-educational approaches designed to facilitate stress reduction and increased confidence to cope with treatment-related side effects⁹⁸.

Implications for prostate cancer disparities

Our limited knowledge about the genetic and other biological events that cause prostate cancer disparities presents a major barrier to eliminating these disparities. The accumulating knowledge of the human genome provides an opportunity to apply knowledge of carcinogenic mechanisms to the problem of prostate cancer disparities. The incorporation of biomarkers in cancer disparities research provides new opportunities for clinical and public health research and practice, and has the potential to catalyze needed improvements in the prevention and management of cancer to eliminate cancer disparities.

Prostate cancer may be a major cancer burden in African men, so it will be important to understand etiological factors including inherited genotypes that confer risk of developing prostate cancer. Understanding

prostate cancer in Africa may inform us about inherited predisposition, modifiable risk factors, and disease prevention in the high risk African American population. Additionally, knowledge of the interactions of prostate cancer susceptibility genes, environment, and behavior could be used to identify individuals at risk of developing prostate cancer with poor outcomes for heightened screening or prevention modalities, and to identify optimal treatment strategies for men of African descent. □

References

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. *Eur J Cancer* 2001;37:S4.
2. Landis SH, Murray T, Bolden S et al. Cancer statistics, 1999. *CA Cancer J Clin* 1999;49:8.
3. Moul JW. Prostate cancer in African American men. *Prostate Cancer Prostatic Dis* 1998;1:109.
4. Hayes RB, Liff JM, Pottner LM et al. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. *Int J Cancer* 1995;60:361.
5. Cunningham GR, Ashton CM, Annegers JF et al. Familial aggregation of prostate cancer in African-Americans and white Americans. *Prostate* 2003;56:256.
6. Thompson I, Tangen C, Tolcher A et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. *J Natl Cancer Inst* 2001;93:219.
7. Koulibaly M, Kabba IS, Cisse A et al. Cancer incidence in Conakry, Guinea: first results from the Cancer Registry 1992-1995. *Int J Cancer* 1997;70:39.
8. Wabinga HR, Parkin DM, Wabwire-Mangen F et al. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. *Int J Cancer* 1993;54:26.
9. Osegbe DN. Prostate cancer in Nigerians: facts and nonfacts. *J Urol* 1997;157:1340.
10. Gueye SM, Zeigler-Johnson CM, Friebe T et al. Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese men. *Urology* 2003;61:987.
11. Ekwere PD, Egbe SN. The changing pattern of prostate cancer in Nigerians: current status in the southeastern states. *J Natl Med Assoc* 2002;94:619.
12. Dawam D, Rafindadi AH, Kalayi GD. Benign prostatic hyperplasia and prostate carcinoma in native Africans. *BJU Int* 2000;85:1074.
13. Kehinde EO. The geography of prostate cancer and its treatment in Africa. *Cancer Surv* 1995;23:281.
14. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA ERA". *Int J Cancer* 2001;92:893.
15. Fowler JE Jr, Bigler SA. Racial differences in prostate carcinogenesis. Histologic and clinical observations. *Urol Clin North Am* 2002;29:183.
16. Bunker CH, Patrick AL, Maharaj G et al. Prostate cancer risk is three-fold higher among men, aged 50-64, of African descent compared with men of Asian-Indian descent in Trinidad and Tobago. *Ethn Dis* 2002;12:S3.
17. Hoffman RM, Gilliland FD, Eley JW et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. *J Natl Cancer Inst* 2001;93:388.

18. Carter BS, Beaty TH, Steinberg GD et al. Mendelian inheritance of familial prostate cancer. *Proc Natl Acad Sci USA* 1992;89:3367.
19. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer— analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000;343:78.
20. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. *J Urol* 1994;152:1484.
21. Ghadirian P, Howe GR, Hislop TG et al. Family history of prostate cancer: a multi-center case-control study in Canada. *Int J Cancer* 1997;70:679.
22. Ross RK, Bernstein L, Lobo RA et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. *Lancet* 1992;339:887.
23. Lookingbill DP, Demers LM, Wang C et al. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. *J Clin Endocrinol Metab* 1991;72:1242.
24. Gann PH, Hennekens CH, Ma J et al. Prospective study of sex hormone levels and risk of prostate cancer. *J Natl Cancer Inst* 1996;88:1118.
25. Oesterling JE, Roy J, Agha A et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. *Urology* 1997;50:13.
26. Nam RK, Toi A, Vesprini D et al. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. *Urology* 2001;57:199.
27. Soderstrom TW, Andersson SO, Johansson JE, Johansson S, Granath F, Rane A. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. *Pharmacogenetics* 2002;12:307.
28. Shibata A, Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, Henderson S, Yemoto CE, Peehl DM. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. *Prostate* 2002;52:269.
29. Jaffe JM, Malkowicz SB, Walker AH et al. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. *Cancer Res* 2000;60:1626.
30. Makridakis NM, Ross RK, Pike MC et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. *Lancet* 1999;354:975.
31. Li Z, Habuchi T, Mitsumori K et al. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. *J Urol* 2003;169:2378.
32. Makridakis N, Ross RK, Pike MC et al. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. *Cancer Res* 1997;57:1020.
33. Lamharzi N, Johnson MM, Goodman G et al. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. *Int J Cancer* 2003;105:480.
34. Lunn RM, Bell DA, Mohler JL et al. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). *Carcinogenesis* 1999;20:1727.
35. Febbo PG, Kantoff PW, Platz EA et al. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. *Cancer Res* 1999;59:5878.
36. Hsing AW, Chen C, Chokkalingam AP et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 2001;10:1077.
37. Pearce CL, Makridakis NM, Ross RK. et al. Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. *Cancer Epidemiol Biomarkers Prev* 2002;11:417.
38. Mononen N, Ikonen T, Syrjakoski K et al. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. *Br J Cancer* 2001;84:1344.
39. Latil AG, Azzouzi R, Cancel GS et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. *Cancer* 2001;92:1130.
40. Giwercman YL, Abrahamsson PA, Giwercman A et al. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. *Eur Urol* 2005;48:679.
41. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat Genet* 2001;27:383.
42. Zeigler-Johnson C, Friebe T, Walker AH et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. *Cancer Res* 2004;64:8461.
43. Plummer SJ, Conti DV, Paris PL et al. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2003;12:928.
44. Waxman DJ, Attisano C, Guengerich FP et al. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. *Arch Biochem Biophys* 1988;263:424.
45. Domanski TL, He YA, Khan KK et al. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. *Biochemistry* 2001;40:10150.
46. Westlind A, Lofberg L, Tindberg N et al. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. *Biochem Biophys Res Commun* 1999;259:201.
47. Amirmani B, Ning B, Deitz AC et al. Increased transcriptional activity of the CYP3A4*1B promoter variant. *Environ Mol Mutagen* 2003;42:299.
48. Amirmani B, Walker AH, Weber BL et al. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. *J Natl Cancer Inst* 1999;91:1588.
49. Ando Y, Tateishi T, Sekido Y et al. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. *J Natl Cancer Inst* 1999;91:1587.
50. Spurdle AB, Goodwin B, Hodgson E et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. *Pharmacogenetics* 2002;12:355.
51. Floyd MD, Gervasini G, Masica AL et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. *Pharmacogenetics* 2003;13:595.
52. Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ et al. Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP. *Mutat Res* 2002;500:103.
53. Domanski TL, Finta C, Halpert JR et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. *Mol Pharmacol* 2001;59:386.
54. Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. *J Pathol* 2001;195:138.
55. Ingles SA, Ross RK, Yu MC et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. *J Natl Cancer Inst* 1997;89:166.
56. Hakimi JM, Schoenberg MP, Rondinelli RH et al. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. *Clin Cancer Res* 1997;3:1599.
57. Zeegers MP, Kiemeny LA, Nieder AM et al. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? *Cancer Epidemiol Biomarkers Prev* 2004;13:1765.

58. Binnie MC, Alexander FE, Heald C et al. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. *Prostate* 2005;63:309.
59. Giwercman C, Giwercman A, Pedersen HS et al. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians. *Int J Androl* 2007.
60. Cude KJ, Montgomery JS, Price DK et al. The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. *Urol Int* 2002;68:16.
61. Giovannucci E, Platz EA, Stampfer MJ et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. *Urology* 1999;53:121.
62. Hsing AW, Gao YT, Wu G et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. *Cancer Res* 2000;60:5111.
63. Vijayalakshmi K, Thangaraj K, Rajender S et al. GGN repeat length and GGN/CAG haplotype variations in the androgen receptor gene and prostate cancer risk in south Indian men. *J Hum Genet* 2006;51:998.
64. Ruhayel Y, Lundin K, Giwercman Y. et al. Androgen receptor gene GGN and CAG polymorphisms among severely oligozoospermic and azoospermic Swedish men. *Hum Reprod* 2004;19:2076.
65. Walker AH, Jaffe JM, Gunasegaram S et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. *Hum Mutat* 1998;12:289.
66. Ross RK, Coetzee GA, Pearce CL et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. *Eur Urol* 1999;35:355.
67. Zeigler-Johnson CM, Walker AH, Mancke B et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. *Hum Hered* 2002;54:13.
68. Tavtigian SV, Simard J, Teng DH et al. A candidate prostate cancer susceptibility gene at chromosome 17p. *Nat Genet* 2001;27:172.
69. Carpten J, Nupponen N, Isaacs S et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. *Nat Genet* 2002;30:181.
70. Xu J, Zheng SL, Komiya A et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. *Nat Genet* 2002;32:321.
71. Zhou A, Hassel BA, Silverman RH. Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. *Cell* 1993;72:753.
72. Zhou A, Paranjape J, Brown TL et al. Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. *Embo J* 1997;16:6355.
73. Rokman A, Ikonen T, Seppala EH et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. *Am J Hum Genet* 2002;70:1299.
74. Rennert H, Bercovich D, Hubert A et al. A Novel Founder Mutation in the RNASEL Gene, 471delAAAAG, Is Associated with Prostate Cancer in Ashkenazi Jews. *Am J Hum Genet* 2002;71:4.
75. Rennert H, Zeigler-Johnson C, Mittal R et al. Analysis of the RNASEL/HPC1, and Macrophage Scavenger Receptor 1 in Asian-Indian Advanced Prostate Cancer
76. Casey G, Neville PJ, Plummer SJ et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. *Nat Genet* 2002;32:581.
77. Platt N, Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional? - The mouse's tale. *J Clin Invest* 2001;108:649.
78. Lieberfarb ME, Lin M, Lechpammer M et al. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. *Cancer Res* 2003;63:4781.
79. Xu J, Zheng SL, Komiya A et al. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. *Am J Hum Genet* 2003;72:208.
80. Takaku H, Minagawa A, Takagi M et al. A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease. *Nucleic Acids Res* 2003;31:2272.
81. Korver W, Guevara C, Chen Y et al. The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex. *Int J Cancer* 2003;104:283.
82. Rebbeck TR, Walker AH, Zeigler-Johnson C. et al. Association of HPC2/ELAC2 genotypes and prostate cancer. *Am J Hum Genet* 2000;67:1014.
83. Wang L, McDonnell SK, Elkins DA et al. Role of HPC2/ELAC2 in hereditary prostate cancer. *Cancer Res* 2001;61:6494.
84. Meitz JC, Edwards SM, Easton DF et al. HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. *Br J Cancer* 2002;87:905.
85. Severi G, Giles GG, Southey MC et al. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. *J Natl Cancer Inst* 2003;95:818.
86. Rennert H, Zeigler-Johnson C.M, Addya K et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. *Cancer Epidemiol Biomarkers Prev* 2005;14:949.
87. Camp NJ, Tavtigian SV. Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. *Am J Hum Genet* 2002;71:1475.
88. Vesprini D, Nam RK, Trachtenberg J et al. HPC2 variants and screen-detected prostate cancer. *Am J Hum Genet* 2001;68:912.
89. Sun J, Hsu FC, Turner AR et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. *Prostate* 2006;66:728.
90. Li H, Tai BC: RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. *Clin Cancer Res* 2006;12:5713.
91. Amundadottir LT, Sulem P, Gudmundsson J et al. A common variant associated with prostate cancer in European and African populations. *Nat Genet* 2006;38:652.
92. Freedman ML, Haiman CA, Patterson N et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. *Proc Natl Acad Sci USA* 2006;103:14068.
93. Gudmundsson J, Sulem P, Manolescu A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. *Nat Genet* 2007;39:631.
94. Haiman CA, Patterson N, Freedman ML et al. Multiple regions within 8q24 independently affect risk for prostate cancer. *Nat Genet* 2007;39:638.
95. Yeager M, Orr N, Hayes RB et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nat Genet* 2007;39:645.
96. Severi G, Hayes VM, Padilla EJ et al. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 2007;16:610.
97. Wang L, McDonnell SK, Slusser JP et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. *Cancer Res* 2007;67:2944.
98. Hughes Halbert C, Armstrong K, Holmes J et al. Transdisciplinary Approaches to Ameliorating Racial Disparities in Prostate Cancer Outcomes. *Journal of Health Disparities Research and Practice* 2006;1:19.

99. Klabunde CN, Potosky AL, Harlan LC. et al. Trends and black/white differences in treatment for nonmetastatic prostate cancer. *Med Care* 1998;36:1337.
100. Desch CE, Penberthy L, Newschaffer CJ et al. Factors that determine the treatment for local and regional prostate cancer. *Med Care* 1996;34:152.
101. Schapira MM, McAuliffe TL, Nattinger AB. Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. *Med Care* 1995;33:1079.
102. Merrill RM, Stephenson RA. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. *J Urol* 2000;163:503.
103. Wong YN, Mitra N, Hudes G et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. *JAMA* 2006;296:2683.
104. Ellison GL, Coker AL, Hebert JR et al. Psychosocial stress and prostate cancer: a theoretical model. *Ethn Dis* 2001;11:484.
105. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC Press, 2002.